Related Experiment Video
Updated: Apr 16, 2026

Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026
Head and neck skin cancer in the immunocompromised patient: a quantitative analysis
Background:
Non-melanoma skin cancers (NMSC) are especially prone to develop in the immunosuppressed population. There is insufficient data regarding outcomes and mortality for immunosuppressed individuals with NMSC of the head and neck.
Clinical Question:
What are the mortality indicators for immunosuppressed subjects with head and neck NMSC?
Methods:
This retrospective chart review analyzes all immunosuppressed patients diagnosed with any stage NMSC at an academic tertiary care institution from 2006-2011.
Results:
Thirty four patients are analyzed. Odds of mortality is significantly increased for patients who required multiple surgeries (adjusted odds ratio (aOR)=23.98, 95%CI=(1.411, 407.599)) and those who were immunocompromised secondary to leukemia (aOR=28.27, 95%CI=(1.838, 434.73)).
Conclusion:
Patients with leukemia and NMSC may have an increased risk of mortality compared to other immunocompromised patients with NMSC. Immunocompromised patients with NMSC may have a worse prognosis if multiple surgeries are required. Knowledge of mortality indicators may aid in the management of these immunocompromised patients.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Tumor Immunotherapy
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...

